Atogepant's Advantage in Chronic Migraine is Illustrated by Phase 3 PROGRESS Results.

Published Date: 04 May 2023

Atogepant 30 mg twice daily and 60 mg once daily reduced monthly migraine days more than placebo did, and a higher proportion of patients experienced a 50% or greater reduction in MMDs over the course of three months.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Targeted radiation therapy shows near-complete response in rare sarcoma patients

2.

Dostarlimab Boosts Long-Term Survival in Endometrial Cancer

3.

Germline Profiling May Improve Risk Stratification in t-MNs

4.

Results for Prostate Cancer Are Associated With PSA Nadir 6 Months After Primary RT.

5.

Scientists call into question safety of potential new anticancer treatment


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot